LB Pharmaceuticals (LBRX) TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit summary

Mechanism and therapeutic profile

• LB-102 is a selective D2, D3, and 5-HT7 inhibitor, designed for improved brain permeability and once-daily dosing compared to amisulpride.

• The drug's bimodal activity allows high doses to suppress dopamine for psychosis and low doses to release dopamine for mood disorders.

• LB-102 aims to treat schizophrenia at 50-100 mg and adjunctive MDD at 15-25 mg, leveraging dose-dependent effects.

Clinical history and efficacy

• Amisulpride, the parent compound, is widely used outside the U.S. for schizophrenia, mood disorders, and anxiety, with strong efficacy and safety data.

• LB-102 is significantly more potent, with 50 mg equivalent to 400 mg of amisulpride.

• Phase II trials showed robust efficacy, especially for negative symptoms and cognition, with low rates of extrapyramidal symptoms (EPS).

Safety, tolerability, and differentiation

• LB-102 demonstrated a low EPS rate (5.6% at highest dose) and minimal sedation (one case in 251 patients) in phase II.

• No anticipated food effect or significant drug-drug interactions, supporting ease of use.

• Potential for best-in-class safety and differentiation in treating negative symptoms and cognitive deficits.